Tumor development, survival, invasion, and metastasis are all affected by these MET mutations, which are found in around 3 to 4% of NSCLC patients.[51] Drugs approved to treat MET exon 14 skipping include capmatinib (TABRECTA) and tepotinib (TEPMETKO).[52]. This evidence concerns the gene MET and neoplasm.